Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06508502 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pancreatitis - Microbiome as Predictor of Severity II

Study acronym: P-MAPS II
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Secondary endpoints: details revised at 5 of 6 entriesv4
  2. Secondary endpoints: 5 to 6 Publications: details revised at 7 of 7 entriesv3 Show 1 more changeShow less
    • Publications: details revised at 7 of 7 entries

    See this version in full on ClinicalTrials.gov ↗

  3. Primary endpoints: 1 to 2 Secondary endpoints revised (5) · Publications: details revised at 7 of 7 entries · Study arms: 2 to 3v2 Show 3 more changesShow less
    • Secondary endpoints revised (5)
    • Publications: details revised at 7 of 7 entries
    • Study arms: 2 to 3

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this observational study is to evaluate the orointestinal microbiome and microbial derived metabolome in patients suffering from acute pancreatitis as a biomarker for severity. The main questions it aims to answer are: * Can the orointestinal microbiome robustly predict the course of acute pancreatitis? * How does the microbiome impact the severity of an acute pancreatitis? Buccal/ rectal swabs, plasma and stool is collected from patients with acute pancreatitis within 48h after hospital admission.
Trial Details
NCT Number NCT06508502
Lead Sponsor University Medical Center Goettingen
Conditions Acute Pancreatitis, Acute Pancreatitis With Infected Necrosis
Enrollment 700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov